MR Imaging Study Using the Northern Alberta Linac-MR (Northern LIGHTs - 1)

Interventional

Phase not listed

Cross Cancer Institute

Cancers are often treated with external beam radiotherapy. Current radiotherapy treatments are performed using computed tomography (also known as CT) scans which may not always clearly identify the cancer. In some instances, magnetic resonance imaging (MRI) may be able to better identify cancers. Therefore, efforts are currently underway to use the MRI scans to improve radiotherapy treatments or eventually even use radiotherapy equipment that only uses MRI scans to guide treatments. This new technology that will only use MRI scans to guide treatments is called the Linac-MR (linear accelerator with an MRI). The purpose of this pilot phase of the study is to test whether the Alberta linac-MR P3 system at the Cross Cancer Institute can acquire high quality MR images safely. It will allow the researchers to develop the best collection of MR images possible with this new machine, in order to allow them to visualize tumors for future patients that are treated on this machine.

Show Detailed Description

Treatment Category

Device

Required Mutations

None

Trial Started

2021-08-23

Last Updated by Sponsor

2025-05-14

Estimated Completion

2029-01-01

Eligibility

Inclusion Criteria

* Adults ≥ 18 years of age

* Patients deemed fit to undergo high dose external beam radiation therapy by their attending radiation oncologist

Exclusion Criteria

* Patients with contraindications for MRI

* Patients who are unable to lie flat and still for the duration of the expected scan acquisition

* Patients who are unable to provide informed consent

Do you think this trial is incorrectly appearing?

Design Details

AllocationN/A

Intervention ModelSingle Group Assignment

MaskingNone (Open Label)

Number to Enroll250

Arms & Interventions

Arms

Interventions

Type: Experimental

Description: All participants will undergo a single MR imaging session (30-40 minutes) on the Alberta linac-MR P3 system.

Interventions:

MR scan with the Alberta linac-MR P3 system

Outcome Measures

Primary Outcome Measures

Number of high-quality MR image data sets acquired for each major tumour site (prostate, liver, lung, CNS, breast, gynecological, pancreas, and head and neck)Through study completion, approximately 7 years

Clinical radiologists, medical physicists, and radiation oncologists will work together to develop MR sequences that can delineate tumour target volumes on the Alberta linac-MR P3 system. Over the course of the trial, the clinical radiologists will work with medical physicists to optimize these sequences to allow for the development of optimal MR images, with the goal to develop of series of protocols that can be utilized to provide clear MR image guidance for each tumour group.

Secondary Outcome Measures

Quantify the patient experience on the Linac-MRAfter the first and last scan, up to 5 weeks

Participants will complete a questionnaire at the end of their first scan regarding their experience having imaging done on the Linac-MR. Participants taking part in the optional sub-study will complete the same questionnaire at the end of their last set of imaging.